Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 46

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 46
---
 the foregoing, our operating loss was $2,065,367 and $2,173,040 for the three months ended September 30,
2025 and 2024, respectively. The decrease was related to cost-cutting initiatives in general and administrative and research and development
expenses.

Other
Income (Expense). Other income (expense) was ($942,442) for the three months ended September 30, 2025 compared to other expense
of ($2,453) for the three months ended September 30, 2024. Other income (expense) in 2025 consisted of unrealized loss on change in derivative
liabilities, amortization of debt discount and interest expense. Other income (expense) in 2024 consisted of interest expense.

Net
Loss. Our net loss for the three months ended September 30, 2025 was $3,007,809 or ($0.11) per share as compared to a net
loss of $2,175,493 or ($0.11) per share for the three months ended September 30, 2024. The increase was primarily related to the
loss on change in derivative liabilities and amortization of debt discount. The weighted average number of shares outstanding was 27,579,136 compared to 20,099,095
for the three months ended September 30, 2025 and 2024, respectively.

For
The Six Months Ended September 30, 2025, Compared to The Six Months Ended September 30, 2024

Total
Revenues. Revenues were $600,784 and $324,470 for the six months ended September 30, 2025 and 2024, respectively. Revenues for
the six months ended September 30, 2025, consist of sales of our Spryng® products of $335,145 and PrecisePRP™ products of $265,639.
Revenues in the six months ended September 30, 2024, consisted of sales entirely of our Spryng® products of $324,470. The increase
in our revenues in the six months ended September 30, 2025, compared to the six months ended September 30, 2024, is due to sales of PrecisePRP™
products, pursuant to our exclusive licensing agreement with VetStem.

Cost
of Sales. Cost of sales were $194,000 and $34,156 for the six months ended September 30,